Edaravone Injection, Solution
NDC 68083-501
Product Information
Edaravone is a ANDA-approved product labeled by Gland Pharma Limited. Edaravone is used to treat a certain type of nerve disease called amyotrophic lateral sclerosis (ALS, also commonly called Lou Gehrig's disease). It is supplied as a injection, solution for intravenous administration. This product entry covers the primary NDC 68083-501 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Code Structure Chart
Product Details
What is NDC 68083-501?
What are the uses of this product?
What are Active Ingredients of this product?
- EDARAVONE 60 mg/100mL - An antipyrine derivative that functions as a free radical scavenger and neuroprotective agent. It is used in the treatment of AMYOTROPHIC LATERAL SCLEROSIS and STROKE.
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- EDARAVONE (UNII: S798V6YJRP)
- EDARAVONE (UNII: S798V6YJRP) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- SODIUM BISULFITE (UNII: TZX5469Z6I)
- CYSTEINE HYDROCHLORIDE (UNII: ZT934N0X4W)
- SODIUM CHLORIDE (UNII: 451W47IQ8X)
- SODIUM HYDROXIDE (UNII: 55X04QC32I)
- PHOSPHORIC ACID (UNII: E4GA8884NN)
- WATER (UNII: 059QF0KO0R)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 1924316 - edaravone 30 MG in 100 ML Injection
- RxCUI: 1924316 - 100 ML edaravone 0.3 MG/ML Injection
- RxCUI: 1924316 - edaravone 30 MG per 100 ML Injection
- RxCUI: 2681044 - edaravone 60 MG in 100 ML Injection
- RxCUI: 2681044 - 100 ML edaravone 0.6 MG/ML Injection
* Please review the full disclaimer at the bottom of this page.